Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis

Link to article at PubMed

Cardiol Clin. 2021 Aug;39(3):389-402. doi: 10.1016/j.ccl.2021.04.010.


Diagnoses of amyloidosis are increasing annually, and advances in bone scintigraphy and cardiac MRI accompanied by development of nonbiopsy diagnostic criteria have specifically led to a huge increase in transthyretin amyloidosis cardiomyopathy (ATTR-CM) diagnoses worldwide. Tafamidis use is increasing, and there are several ongoing phase III clinical trials of novel agents that promise to transform the treatment landscape for patients with ATTR-CM. In systemic light chain (AL) amyloidosis, more effective chemotherapeutic agents continue to improve patient outcomes. Accelerating the removal of amyloid deposits to accompany these therapies remains the holy grail. However, in the meantime, early diagnosis is undoubtedly key in improving patient outcomes.

PMID:34247752 | DOI:10.1016/j.ccl.2021.04.010

Leave a Reply

Your email address will not be published.